LEADER 03928nam  2200949z- 450 
001 9910367753903321
005 20231214133528.0
010   $a3-03921-587-6
035   $a(CKB)4100000010106178
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/40955
035   $a(EXLCZ)994100000010106178
100   $a20202102d2019      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aAnticancer Drugs
210   $cMDPI - Multidisciplinary Digital Publishing Institute$d2019
215   $a1 electronic resource (214 p.)
311   $a3-03921-586-8 
330   $aThe past decades have seen major developments in the understanding of the cellular and molecular biology of cancer. Significant progress has been achieved regarding long-term survival for the patients of many cancers with the use of tamoxifen for treatment of breast cancer, treatment of chronic myeloid leukaemia with imatinib, and the success of biological drugs. The transition from cytotoxic chemotherapy to targeted cancer drug discovery and development has resulted in an increasing selection of tools available to oncologists. In this Special Issue of Pharmaceuticals, we highlight the opportunities and challenges in the discovery and design of innovative cancer therapies, novel small-molecule cancer drugs and antibody?drug conjugates, with articles covering a variety of anticancer therapies and potential relevant disease states and applications. Significant efforts are being made to develop and improve cancer treatments and to translate basic research findings into clinical use, resulting in improvements in survival rates and quality of life for cancer patients. We demonstrate the possibilities and scope for future research in these areas and also highlight the challenges faced by scientists in the area of anticancer drug development leading to improved targeted treatments and better survival rates for cancer patients.
610   $agraphene oxide
610   $aindole
610   $aandrogens
610   $acyclooxygenase-2
610   $acyclooxygenase-1
610   $aheteropolysaccharide
610   $adrug conjugation
610   $adrug delivery
610   $aellipticine
610   $achemical linker
610   $aoesophageal cancer
610   $aantiproliferative activity
610   $atopoisomerase II
610   $a?-lactam
610   $aDSD
610   $aantibody
610   $atopoisomerase inhibitors
610   $amagnetic targeting
610   $acisplatin resistance
610   $asteroidogenesis
610   $a[18F]FDG PET/CT
610   $aheterocyclic chemistry
610   $adehydroepiandrosterone
610   $aantimitotic
610   $a3-vinylazetidin-2-ones
610   $aglioblastoma
610   $aand cancer therapy
610   $aintestinal mucositis
610   $aCombretastatin A-4
610   $ametabolism
610   $aanti-cancer drugs
610   $amaghemite
610   $aCOX-1 inhibitor
610   $aanticancer
610   $aCYP17A1
610   $aconjugate and hybrid drugs
610   $ainflammation
610   $asnticancer drugs
610   $aP450c17
610   $atumorigenesis
610   $acisplatin
610   $abiomarker profiling
610   $acancer drug design
610   $atubulin
610   $acytochrome P450
610   $a5-fluorouracil
610   $aprostate cancer
610   $aabiraterone
610   $aNCI screen
610   $aradiation
610   $acancer immunotherapy
610   $amicrotubule targeted drugs
610   $acancer
610   $atreatment resistance
700   $aO?Boyle$b Niamh M$4auth$01296346
702   $aMeegan$b Mary J$4auth
906   $aBOOK
912   $a9910367753903321
996   $aAnticancer Drugs$93024025
997   $aUNINA